The Safety and Immunogenicity Study of the Recombinant Zoster Vaccine (CHO Cell)

NCT05769049 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

48

Enrollment

INDUSTRY

Sponsor class

Conditions

Herpes Zoster

Interventions

BIOLOGICAL: REC610
BIOLOGICAL: Shingrix

Sponsor

Jiangsu Rec-Biotechnology Co., Ltd.